Director/PDMR Shareholding

December 17, 2021

RNS Number : 0593W
Renalytix PLC
17 December 2021

Renalytix plc
("**Renalytix**" or the "**Company**")

Director/PDMR Dealing

New York, 17 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase by Ann Berman, the Company's Non-Executive Director, of 3,000 American Depositary Shares ("**ADS**") in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("**Ordinary Shares**"), at an aggregate price of $14.00 per ADS.

Following completion of the purchase, Ann Berman is interested in 12,000 Ordinary Shares representing 0.02% of the current issued share capital of the Company.

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	**Via Walbrook PR**
Stifel (Nominated Adviser, Joint Broker)	**Tel: 020 7710 7600**
Alex Price / Nicholas Moore	
Investec Bank plc (Joint Broker)	**Tel: 020 7597 4000**
Gary Clarence / Daniel Adams	
Walbrook PR Limited	**Tel: 020 7933 8780** or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth	Mob: 07980 541 893 / 07584 391 303

About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for

drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

The information contained in this notification is disclosed in accordance with the requirements of MAR.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Ann Berman
2	**Reason for the notification**	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Renalytix plc
b)	Legal Entity Identifier	213800NTOH3FK3WER551
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument	ADS', each ADS representing two Ordinary Shares of £0.0025 each.
	Identification code	US75973T1016
b)	Nature of the transaction	Purchase of ADS'
c)	Currency	US Dollar

d)	Price(s) and volume(s)	Price(s)	Volume(s)
		$14.00	3,000 ADS (representing 6000 Ordinary Shares)
e)	Aggregated information - Aggregated volume	3,000 ADS (representing 6,000 Ordinary Shares)	

	- Price - Aggregated total	$14.00 $42,000
f)	Date of the transaction	16 December 2021
g)	Place of the transaction	Nasdaq Stock Exchange

END

DSHEAFAXFAFFFFA